Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
A Tale of Two (or More) Targets: What We’ve Learned Building Multispecifics for Our Partners
Alloy’s perspective on the multispecific engineering problem Most protein engineers designing multispecifics today learned the craft on monoclonals, and some of the discovery and development infrastructure followed the same path. That’s a reasonable starting point. It’s also where a lot of the late-stage surprises come from. Multispecific antibodies aren’t just harder monoclonals. They’re a fundamentally […]
Rethinking Antisense Architecture with Transient Cyclic Oligonucleotides for Next-Generation RNA Therapeutics
Author: Christian Cobaugh, CEO, Genetic Medicine Division at Alloy Therapeutics RNA therapeutics are moving from promise to reality. By operating upstream of protein targets and closer to the genetic root causes of many diseases, RNA medicines often offer treatment approaches that differ fundamentally from conventional small molecules or biologics. Antisense molecules have evolved from conceptual […]
Overcoming Antibody Discovery Challenges Against GPCR Targets
Generate high-quality therapeutic leads for GPCR targets in just 12 weeks with next-generation antibody discovery workflows The therapeutic promise of GPCR-targeted monoclonal antibodies G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors, serving as critical signaling nodes across all major physiological systems. These seven-transmembrane proteins control essential functions in metabolism, immunity, and […]
How AI is reshaping antibody discovery and optimization workflows
In silico antibody discovery and optimization: How computational tools are reshaping the workflow AI-enabled and ML-powered methods are enabling faster identification and engineering of high-quality therapeutic antibody leads The field of antibody discovery is experiencing a transformative shift through the integration of cutting-edge artificial intelligence (AI) and machine learning (ML) technologies. Traditional methods of antibody […]
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Alloy Therapeutics enables high-throughput CAR discovery and engineering by providing diverse binder sets from its ATX-Gx™ and ATX-SiD platforms to optimize antigen specificity and affinity. Their Discovery Services offer comprehensive functional screening in primary immune cells—including expression, activation, and cell-killing assays—to streamline the development of next-generation CAR-T, NK, and macrophage therapies. Cell therapy utilizing chimeric […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Alloy Therapeutics is democratizing access to foundational drug delivery, formulation, and half-life extension technologies to overcome critical barriers such as molecular stability and crossing the blood-brain barrier. Through its Innovation Subscription model and collaborations with institutions like MIT’s Marble Center, Alloy provides the drug discovery community with validated, pre-competitive delivery platforms including LNPs and antibody-drug […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Alloy Will Help the Drug Discovery Community Unlock the Therapeutic Potential of ASOs
Alloy Therapeutics is expanding into genetic medicines with its ASO Discovery Services group, offering democratized access to novel chemistries, bioinformatics-driven design, and ASO-antibody conjugates. Led by industry pioneers Dr. Sudhir Agrawal and Dr. Ben Chih, this initiative aims to overcome historical toxicity and accessibility barriers to unlock the full therapeutic potential of antisense oligonucleotides. Our […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]